Subscribe - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 April 2018

Advanced search - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder


Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links

Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

Question Time

HepatologyLiver diseases

Chronic hepatitis

Click a heading in the right-hand column to see the selected questions in that subject area

Please submit a new question (maximum 100 words) to Please note that this service is only for medically qualified professionals, and not for the general public. The questions should ask a technical question about a topic in gastroenterology, hepatology or endsocopy. You may nominate the expert from our Global Academic Faculty whom you would like us to contact for the first reply. Don't forget to include your full name, city, country and your email address.

Which anti-tuberculosis drugs, and in what doses, should be used in a patients with chronic liver disease?

Muhammad Iqbal, Rawalpindi, Pakistan  27 September 2002

The treatment of tuberculosis in patients with chronic liver disease is challenging, and risks versus benefits must be weighed. Potentially hepatotoxic agents include: isoniazid, pyrazinamide, rifampin, and ethionamide. Streptomycin and ethambutol appear to be free of hepatotoxicity. Active tuberculosis requires therapy in the patient with chronic liver disease, while treatment of latent tuberculosis infection might be deferred if the liver disease is likely to improve with therapy or further follow-up. Active hepatitis and end-stage liver disease are relative contraindications to the use of isoniazid or pyrazinamide for the treatment of latent tuberculosis infection.

The American Thoracic Society and Centers for Disease Control and Prevention (CDC) published recommendations regarding treatment of latent tuberculosis infection in 2000 [1]. Four regimens were recommended for the treatment of latent tuberculosis infection in adults: (1) isoniazid daily or twice weekly for 9 months;( 2) isoniazid daily or twice weekly for 6 months; (3) rifampin/pyrazinamide daily for 2 months or twice weekly for 2-3 months; or (4) ripampin daily for 4 months. The isoniazid daily regimen for 9 months is preferred, based on prospective trials.

Recent reports of fatal and severe hepatotoxicity with the rifampin/pyrazinamide 2-month regimen has led to the further recommendation that this regimen should be used with caution, especially in patients taking other medications that might be hepatotoxic or with a history of alcohol abuse [2]. The American Thoracic Society/CDC recommended that patients who are known to have a chronic liver disease, have risk factors for liver disease, or abuse alcohol should have baseline serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin.

Patients with mild or moderate liver disease who undergo treatment with isoniazid alone or rifampicin alone should be monitored by clinical evaluation and liver tests at least monthly. Most expert recommend that isoniazid should be stopped if a patient's aminotransferase level exceed 3 times the upper limit of normal if associated with symptoms and five times the upper limit of normal in the patient is asymptomatic. There are no recommendations for alternative doses of antituberculosis drugs in patients with liver disease.


  1. American Thoracic Society, CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Resp Crit Care Med 2000;161:S221-SD247.
  2. CDC. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations United States, 2001. MMWR 2001;50:733-735.

Emmet Keeffe, Palo Alto, CA, USA  27 September 2002

DISCLAIMER: Question Time is for information only and is not a substitute for specific medical advice and diagnosis from a medical practitioner. Neither the content providers nor the publisher accept any legal responsibility for nor make any warranty with respect to the views expressed or procedures outlined on the site.


Go to top of page Email this page Email this page to a colleague

Close folder Gastroenterology
Stomach & duodenum
Helicobacter pylori
Small intestine
Colo-rectum and anus
Inflammatory bowel disease
Functional bowel disorders
Symptoms/signs of gastrointestinal disease
Basic science
Close folder Hepatology
Biliary tract
Viral hepatitis
  Liver diseases
Cirrhosis and portal hypertension
Liver transplantation
Liver & other diseases
Pediatric hepatology
Basic science
Close folder Endoscopy
Upper endoscopy
Endoscopic ultrasound
Practice issues

Blackwell Publishing is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and and contributors
Privacy Statement
About Us